Events Calendar

Download as iCal file
Professor Mari Dezawa
Tuesday, April 03, 2018, 12:00pm - 01:00pm

mari dezawa d227eProfessor Mari Dezawa

Tohoku University

Tuesday April 3, 2018

12:00PM, Life Sciences Auditorium

“Endogenous Reparative Muse Cells Provide the Concept of Next-Generation Medical Treatment”

Multilineage-differentiating stress enduring (Muse) cells are naturally existing unique endogenous stem cells that are non-tumorigenic and are pluripotent-like. They express pluripotent markers, can generate cells representative of all three germ layers from a single cell and are able to self-renew. Since they express specific receptor for damage signal, sphingosine-1-phosphate (S1P receptor2), they can preferentially home into S1P-producing damaged site after intravenous injection with lower entrapment in the lung and spleen. After integration, they
replenish lost cells by spontaneous differentiation into tissue-compatible cells, leading to robust tissue and functional regeneration. The unique reparative functions of Muse cells were
demonstrated in animal models of liver cirrhosis, stroke, chronic kidney disease and acute myocardial infarction (AMI). They do not have to be “induced,” or genetically manipulated, to be pluripotent or be purposive cells before administration. They can be collected as cells positive for SSEA-3, a surface marker for pluripotent stem cells, from readily accessible sources such as the bone marrow (~0.03% of the total mononucleated cell population), and from commercially available cultured fibroblasts (several %). Recently, Muse cells are shown to circulate in peripheral blood in healthy donors, and the number increases in stroke and AMI patients in an acute phase, suggesting that endogenous Muse cells are mobilized into peripheral blood to repair tissues while their number is not sufficient to recover, and that supply of exogenous Muse cells is expected to deliver statistically meaningful functional recovery. Overall, Muse cells are a feasible source for cell-based approaches?and may safely provide clinically relevant regenerative effects compatible with the ‘body’s natural
repair systems’ by simple cost-effective strategy-collection of Muse cells from sources, large scale expansion and intravenous injection. Currently, the phase I clinical study targeting AMI is conducted by Mitsubishi Chemical Holdings.

~Coffee/tea will be served prior to lecture~